[The dose of alpha interferon in induction and maintainance therapy of hairy cell leukemia].
The efficacy of different doses of interferon (IFN) alpha in the induction therapy of hairy cell leukemia was studied. Recombinant IFN alpha-2b was administered subcutaneously every second day at an initial dose of 4 x 10(6) U/m2 (7 patients), 2 x 10(6) U/m2 (14 patients) and 1 x 10(6) U/m2 (13 patients). Each dose was effective to induce a normalization of blood cell counts and a reduction of bone marrow infiltration in the majority of patients treated. A delayed increase in granulocyte counts, however, was noted in patients treated with 1 x 10(6) U/m2, and 2 of them only achieved a partial hematological remission after 1 year of treatment. After the induction of stable remission, patients were randomized into 2 different schedules of maintenance therapy. Five of 7 patients receiving IFN alpha-2b at a total dose of 1 x 10(6) U twice a week, and 6/8 patients treated with 2 x 10(6) U once weekly, respectively, received this therapy for 1 year and remained in stable remission.
Kloke
O
O
Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum, Essen.
May
D
D
Wandl
U
U
Niederle
N
N
D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D007370:Interferon Type I / Q000008:administration & dosage*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D007943:Leukemia, Hairy Cell / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012074:Remission Induction / Q000379:methods
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Zur Dosierung von Interferon alpha in der Induktions- und Erhaltungstherapie der Haarzellenleukämie.